Arcadia Biosciences, Inc. reported a total revenue of $4.86 million for the fiscal year ending December 31, 2025, a decrease of 4% from $5.05 million in 2024. The decline was primarily attributed to the cessation of GLA oil sales, which had generated $756,000 in revenue in the previous year. However, sales of Zola coconut water increased by 17%, contributing $701,000 to the overall revenue growth. The company recorded a net loss of $2.34 million, a significant improvement compared to the $7.04 million loss reported in the prior year, reflecting a 67% reduction in losses.
In terms of operational changes, Arcadia made strategic decisions to divest from certain product lines, including the sale of its GoodWheat brand to Above Food for $3.7 million and the non-GMO Resistant Starch durum wheat trait to Corteva Agriscience for $4 million. These transactions were aimed at monetizing intellectual property and streamlining operations. Additionally, the company has exited its agronomic wheat traits business, which has eliminated future royalty revenues from this segment.
The company’s operational metrics indicate a reduction in employee headcount, with only eight employees reported as of December 31, 2025, down from previous years. This reduction has raised concerns regarding the company's ability to maintain effective internal controls, as noted in their 10-K filing, which identified material weaknesses in internal control over financial reporting. The company is actively working on remediation plans to address these deficiencies.
Looking ahead, Arcadia faces significant challenges, including a substantial doubt about its ability to continue as a going concern due to limited cash resources, which stood at $259,000 as of December 31, 2025. The company anticipates needing additional funding to support its operations and marketing efforts. The recent default by Above Food on a $6 million promissory note has further complicated the financial outlook, leading to a credit loss of $4.7 million being recognized in the current fiscal year. The company is exploring various financing options, including potential equity or debt offerings, to secure the necessary capital for future operations.
About Arcadia Biosciences, Inc.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.